ERBB2 and neoplasm: Whereas 137/209 (65.5%) of all HR+HER2- tumors were considered High-Risk by MammaPrint and were more likely to have a pCR with NAC, no HR+HER2− MammaPrint Low-Risk tumor had a pCR with NAC.